Drug-Induced Thrombophilic or Prothrombotic States: An Underestimated Clinical Problem That Involves Both Legal and Illegal Compounds

Clinical and Applied Thrombosis/Hemostasis

Volumn 23, Issue 7, 2017, Pages 775-785

  Girolami, A ^a   Cosi, E ^a   Tasinato, V ^a   Santarossa, C ^a   Ferrari, S ^a   Girolami, B ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b Universit degli Studi di Padova   (Italy)

Author keywords

drugs; hypercoagulable state; prothrombotic state; thrombosis

Indexed keywords

ANABOLIC AGENT; ANTIFIBRINOLYTIC AGENT; ASPARAGINASE; BLEOMYCIN; CANNABIS; CISPLATIN; COCAINE; CORTISONE; CYCLOSPORIN; DANAZOL; DESMOPRESSIN; ERYTHROPOIETIN; HEPARIN; ILLICIT DRUG; IMMUNOGLOBULIN; MITOMYCIN; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; SILDENAFIL; TAMOXIFEN; TESTOSTERONE; THALIDOMIDE DERIVATIVE;

ENERGY DRINK; EPHEDRA; GUARANA; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VEIN THROMBOSIS; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; THROMBOPHILIA;

DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 85029754786     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616652724     Document Type: Review

References (111)

1. Klöcking HP,. Generation of thrombophilic states by drugs. Folia Haematol Int Mag Klin Morphol Blutforsch. 1984; 111 (4): 441-449.
2. Ramot Y, Nyska A,. Drug-induced thrombosis-experimental, clinical, and mechanistic considerations. Toxicol Pathol. 2007; 35 (2): 208-225.
3. Ramot Y, Nyska A, Spectre G,. Drug-induced thrombosis: an update. Drug Saf. 2013; 36 (8): 585-603.
4. Girolami A, Cliffton EE,. Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid. Thromb Diath Haemorrh. 1967; 17 (1-2): 165-175.
5. Anderson JA, Weitz JI,. Hypercoagulable states. Crit Care Clin. 2011; 27 (4): 933-952.
6. Hassouna HI,. Thrombophilia and hypercoagulability. Med Princ Pract. 2009; 18 (6): 429-440.
7. Engelmann L., Thrombophilic states in intensive care medicine [in German]. Med Klin Intensivmed Notfmed. 2011; 106 (3): 189-197.
8. Martinelli I, Passamonti SM, Bucciarelli P,. Thrombophilic states. Handb Clin Neurol. 2014; 120: 1061-1071.
9. Girolami A, Ruzzon E, Fabris F, Varvarikis C, Sartori R, Girolami B,. Myocardial infarction and other arterial occlusions in hemophilia A patients. A cardiological evaluation of all 42 cases reported in the literature. Acta Haematol. 2006; 116 (2): 120-125.
10. Girolami A, Tezza F, Scapin M, Vettore S, Casonato A,. Arterial and venous thrombosis in patients with von Willebrand's disease: a critical review of the literature. J Thromb Thrombolysis. 2006; 21 (2): 175-178.
11. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B,. Arterial and venous thrombosis in rare congenital bleeding disorders: a critical review. Haemophilia. 2006; 12 (4): 345-351.
12. Batty P, Honke A, Bowles L, et al. Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres. Haemophilia. 2015; 21 (4): 490-495.
13. Bolton-Maggs P, Goudemand J, Hermans C, Makris M, de Moerloose P,. FXI concentrate use and risk of thrombosis. Haemophilia. 2014; 20 (4): e349-e351.
14. Girolami A, Bertozzi I, Rigoni I, Muzzolon R, Vettore S,. Congenital FVII deficiency and thrombotic events after replacement therapy. J Thromb Thrombolysis. 2011; 32 (3): 362-367.
15. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A,. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis. 1992; 3 (6): 789-793.
16. Dal Bo Zanon R, Fornasiero L, et al. Clotting changes in Cushing's syndrome: elevated factor VIII activity. Folia Haematol Int Mag Klin Morphol Blutforsch. 1983; 110 (2): 268-277.
17. Casonato A, Pontara E, Boscaro M, et al. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagul Fibrinolysis. 1999; 10 (3): 145-151.
18. Boscaro M, Sonino N, Scarda A, et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab. 2002; 87 (8): 3662-3666.
19. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR,. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet. 1995; 345 (8943): 152-155.
20. Vandenbroucke JP, Rosing J, Bloemenkamp KW, et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001; 344 (20): 1527-1535.
21. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR,. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009; 339: b2921.
22. Girolami A, Spiezia L, Girolami B, Zocca N, Luzzatto G,. Effect of age on oral contraceptive-induced venous thrombosis. Clin Appl Thromb Hemost. 2004; 10 (3): 259-263.
23. Girolami A, Scandellari R, Spiezia L, Tezza F,. Previous thrombosis-free pregnancies are no guarantee that subsequent oral contraception may also remain asymptomatic. J Thromb Thrombolysis. 2008; 26 (1): 62-63.
24. Han L, Jensen JT,. Does the progestogen used in combined hormonal contraception affect venous thrombosis risk? Obstet Gynecol Clin North Am. 2015; 42 (4): 683-698.
25. Rott H,. Prevention and treatment of venous thromboembolism during HRT: current perspectives. Int J Gen Med. 2014; 7: 433-440.
26. Mor YS, Schenker JG,. Ovarian hyperstimulation syndrome and thrombotic events. Am J Reprod Immunol. 2014; 72 (6): 541-548.
27. Girolami A, Scandellari R, Tezza F, Paternoster D, Girolami B,. Arterial thrombosis in young women after ovarian stimulation: case report and review of the literature. J Thromb Thrombolysis. 2007; 24 (2): 169-174.
28. Jóawik M,. The mechanism of thromboembolism in the course of ovarian hyperstimulation syndrome. Med Wieku Rozwoj. 2012; 16 (4): 269-271
29. Kasum M, Danoli D, Oreškovi S, Je3/4ek D, Beketi-Oreškovi L, Pekez M,. Thrombosis following ovarian hyperstimulation syndrome. Gynecol Endocrinol. 2014; 30 (11): 764-768.
30. Westerlund E, Henriksson P, Wallén H, Hovatta O, Wallberg KR, Antovic A,. Detection of a procoagulable state during controlled ovarian hyperstimulation for in vitro fertilization with global assays of haemostasis. Thromb Res. 2012; 130 (4): 649-653.
31. Taparia M, Cordingley FT, Leahy MF,. Pulmonary embolism associated with tranexamic acid in severe acquired haemophilia. Eur J Haematol. 2002; 68 (5): 307-309.
32. Mihalache RM, Ames PR,. Deep vein thrombosis, tranexamic acid, and a negative d-Dimer. Clin Appl Thromb Hemost. 2012; 18 (6): 666-667.
33. Sundström A, Seaman H, Kieler H, Alfredsson L,. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG. 2009; 116 (1): 91-97.
34. Woo KS, Tse LK, Woo JL, Vallance-Owen J,. Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy. Br J Clin Pract. 1989; 43 (12): 465-466.
35. Endo Y, Nishimura S, Miura A,. Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura. JAMA. 1988; 259 (24): 3561-3562.
36. Gobbi F,. L'acido epsilon-aminocaproico nel trattamento dell' emofilia. Clin Ter. 1968; 46 (1): 55-72.
37. Marwali MR, Mehta JL,. COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies. Thromb Haemost. 2006; 96 (4): 401-406.
38. Nissen SE,. Adverse cardiovascular effects of rofecoxib. N Engl J Med. 2006; 355 (2): 203-204.
39. Weir MR, Sperling RS, Reicin A, Gertz BJ,. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J. 2003; 146 (4): 591-604.
40. Krötz F, Struthmann L,. A review on the risk of myocardial infarction associated with the NSAID diclofenac. Cardiovasc Hematol Disord Drug Targets. 2010; 10 (1): 53-56.
41. Chen LC, Ashcroft DM,. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials. Pharmacoepidemiol Drug Saf. 2007; 16 (7): 762-772.
42. Hägg S, Jönsson AK, Spigset O,. Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf. 2009; 8 (5): 537-547.
43. Kleijer BC, Heerdink ER, Egberts TC, Jansen PA, van Marum RJ,. Antipsychotic drug use and the risk of venous thromboembolism in elderly patients. J Clin Psychopharmacol. 2010; 30 (5): 526-530.
44. Parker C, Coupland C, Hippisley-Cox J,. Antipsychotic drugs and risk of venous thromboembolism: nested case-control study. BMJ. 2010; 341: c4245.
45. Reitsma PH, Bertina RM, Ploos van Amstel JK, Riemens A, Briët E,. The putative factor IX gene promoter in hemophilia B Leyden. Blood. 1988; 72 (3): 1074-1076.
46. Windecker S, Meier B,. Late coronary stent thrombosis. Circulation. 2007; 116 (17): 1952-1965.
47. Liljeqvist S, Helldén A, Bergman U, Söderberg M,. Pulmonary embolism associated with the use of anabolic steroids. Eur J Intern Med. 2008; 19 (3): 214-215.
48. Alvarado RG, Liu JY, Zwolak RM,. Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg. 2001; 34 (6): 1123-1126.
49. Satake R, Arakawa S, Hashimoto M, Minamide H, Takamori M,. Successful direct thrombolysis in a patient with extensive dural sinus thrombosis induced by danazol [in Japanese]. Rinsho Shinkeigaku. 1997; 37 (4): 309-313.
50. al-Momen AK, Huraib SO, Gader AM, Sulaimani F,. Low dose danazol is effective in management of erythropoietin induced thrombosis. Thromb Res. 1991; 64 (5): 527-532.
51. Glueck CJ, Goldenberg N, Budhani S, et al. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. Transl Res. 2011; 158 (4): 225-234.
52. Glueck CJ, Richardson-Royer C, Schultz R, et al. Testosterone, thrombophilia, and thrombosis. Clin Appl Thromb Hemost. 2014; 20 (1): 22-30.
53. Higgins JP, Tuttle TD, Higgins CL,. Energy beverages: content and safety. Mayo Clin Proc. 2010; 85 (11): 1033-1041.
54. Benjo AM, Pineda AM, Nascimento FO, Zamora C, Lamas GA, Escolar E,. Left main coronary artery acute thrombosis related to energy drink intake. Circulation. 2012; 125 (11): 1447-1448.
55. Sachdeva R, Sivasankaran S, Fishman RF, Zarich SW, McPherson CA,. Coronary thrombosis related to use of Xenadrine RFA. Tex Heart Inst J. 2005; 32 (1): 74-77.
56. Thomas JE, Munir JA, McIntyre PZ, Ferguson MA,. STEMI in a 24-year-old man after use of a synephrine-containing dietary supplement: a case report and review of the literature. Tex Heart Inst J. 2009; 36 (6): 586-589.
57. Lisse JR, Davis CP, Thurmond-Anderle ME,. Upper extremity deep venous thrombosis: increased prevalence due to cocaine abuse. Am J Med. 1989; 87 (4): 457-458.
58. Mirzayan R, Hanks SE, Weaver FA,. Cocaine-induced thrombosis of common iliac and popliteal arteries. Ann Vasc Surg. 1998; 12 (5): 476-481.
59. Mochizuki Y, Zhang M, Golestaneh L, Thananart S, Coco M,. Acute aortic thrombosis and renal infarction in acute cocaine intoxication: a case report and review of literature. Clin Nephrol. 2003; 60 (2): 130-133.
60. Paulin Vera CM, Mateos Colin A, Calvo Arrojo G, Colodro García JM,. Acute aortoiliac thrombosis due to cocaine intake. Ann Vasc Surg. 2013; 27 (2): 239. e1-e4.
61. Webber J, Kline RA, Lucas CE,. Aortic thrombosis associated with cocaine use: report of two cases. Ann Vasc Surg. 1999; 13 (3): 302-304.
62. Worthley MI, Prabhu A, De Sciscio P, Schultz C, Sanders P, Willoughby SR,. Detrimental effects of energy drink consumption on platelet and endothelial function. Am J Med. 2010; 123 (2): 184-187.
63. Cuzick J,. Tamoxifen and the factor V Leiden mutation. J Natl Cancer Inst. 2010; 102 (13): 918-919.
64. Erman M, Abali H, Oran B, et al. Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol. 2004; 15 (11): 1622-1626.
65. Hutchison RL, Rayan GM,. Thrombosis of digital arteries associated with tamoxifen use: case report. J Reconstr Microsurg. 2012; 28 (2): 145-148.
66. Onitilo AA, McCarty CA, Wilke RA, et al. Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. Breast Cancer Res Treat. 2009; 115 (3): 643-650.
67. Shah VP, Chegini HA, Vishneski SR, Weatherman RV, Blackmore PF, Dobrydneva Y,. Tamoxifen promotes superoxide production in platelets by activation of PI3-kinase and NADPH oxidase pathways. Thromb Res. 2012; 129 (1): 36-42.
68. Dicato M,. Venous thromboembolic events and erythropoiesis-stimulating agents: an update. Oncologist. 2008; 13 (suppl 3): 11-15.
69. Karabinos IK, Koulouris S, Kranidis A, et al. Spontaneous thrombus formation in a normal left ventricle following administration of large doses of epoetin. Hellenic J Cardiol. 2007; 48 (1): 44-46.
70. Lippi G, Franchini M, Favaloro EJ,. Thrombotic complications of erythropoiesis-stimulating agents. Semin Thromb Hemost. 2010; 36 (5): 537-549.
71. Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL,. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood. 2009; 113 (10): 2161-2171.
72. Ghanima W, Lee SY, Barsam S, Miller A, Sandset PM, Bussel JB,. Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists. Br J Haematol. 2012; 158 (6): 811-814.
73. Darnige L, Lillo-Le Louët A,. Treatments with immunoglobulin and thrombotic adverse events [in French]. Rev Med Interne. 2014; 35 (1): 39-44.
74. Lorenzana A, Armin S, Sharma A, Allarakhia I, Witkowski A,. Cerebral infarctions after intravenous immunoglobulin therapy for ITP in a child. Pediatr Neurol. 2014; 50 (2): 188-191.
75. Desmopressin and arterial thrombosis [editorial]. Lancet. 1989; 1 (8644): 938-939.
76. Girolami A, Vettore S, Fabris F,. Selection of both normal and bleeding patients is indicated before desmopressin administration. Thromb Haemost. 2005; 93 (6): 1198.
77. Pentimone F, Del Corso L,. Trombosi venosa degli arti inferiori ed embolia polmonare dopo desmopressina: coincidenza o ruolo patologico? Clin Ter. 1991; 139 (1-2): 49-51.
78. Osman K, Comenzo R, Rajkumar SV,. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001; 344 (25): 1951-1952.
79. Scarpace SL, Hahn T, Roy H, et al. Arterial thrombosis in four patients treated with thalidomide. Leuk Lymphoma. 2005; 46 (2): 239-242.
80. Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M,. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis. 2009; 20 (5): 337-339.
81. Chennuru S, Baumann MA,. Deep vein thrombosis occurring on treatment of patients receiving thalidomide with erythropoietin. Intern Med J. 2007; 37 (7): 506-507.
82. Palumbo A, Palladino C,. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012; 3 (5): 255-266.
83. Wu JS, Poon WT, Ma CK, et al. Budd-Chiari syndrome secondary to toxic pyrrolizidine alkaloid exposure. Hong Kong Med J. 2013; 19 (6): 553-555.
84. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992; 68 (1): 95-96.
85. Warkentin TE, Greinacher A,. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126 (3 suppl): 311-337.
86. Girolami B, Girolami A,. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost. 2006; 32 (8): 803-809.
87. Warkentin TE, Sheppard JA, Manheim JC,. HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HIT. Thromb Haemost. 2014; 112 (6): 1319-1322.
88. Solak Y, Demircioglu S, Polat I, et al. Heparin-induced thrombocytopenia in a hemodialysis patient treated with fondaparinux: nephrologists between two fires. Hemodial Int. 2013; 17 (2): 320-323.
89. Rota E, Bazzan M, Fantino G,. Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008; 99 (4): 779-781.
90. D'Angelo A, Valle PD, Fattorini A, Luciano C,. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration in a patient with DVT associated with LMWH-induced thrombocytopenia. Thromb Haemost. 2006; 95 (3): 573-575.
91. Carneiro AM, Barthelmes D, Falcão MS, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011; 225 (4): 211-221.
92. Semeraro F, Morescalchi F, Duse S, Gambicorti E, Romano MR, Costagliola C,. Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview. Expert Opin Drug Saf. 2014; 13 (6): 785-802.
93. Akyuz F, Akyuz U, Kocaman O, Kaymakoglu S,. Rare complication of interferon alpha therapy: retinal vein thrombosis. Acta Gastroenterol Belg. 2005; 68 (3): 394-395.
94. Ortega-Ibarra FS, Remes-Troche JM,. Retinal thrombosis secondary to the combination therapy of pegylated interferon and ribavirin for chronic hepatitis C virus infection. A rare complication. Rev Esp Enferm Dig. 2013; 105 (5): 291-292.
95. Nazir L, Husain A, Haroon W, Shaikh MI, Mirza SA, Khan Z,. Interferon-induced central retinal vein thrombosis. J Coll Physicians Surg Pak. 2012; 22 (11): 735-736.
96. Velásquez López JG, Agudelo Restrepo CA, Yepes Gómez D, Uribe Trujillo CA,. Acute myocardial infarction associated to the sildenafil consumption. A case report and review of the literature [in Spanish]. Actas Urol Esp. 2007; 31 (1): 52-57.
97. Porter A, Mager A, Birnbaum Y, Strasberg B, Sclarovsky S, Rechavia E,. Acute myocardial infarction following sildenafil citrate (Viagra) intake in a nitrate-free patient. Clin Cardiol. 1999; 22 (11): 762-763.
98. Feenstra J, van Drie-Pierik RJ, Laclé CF, Stricker BH,. Acute myocardial infarction associated with sildenafil. Lancet. 1998; 352 (9132): 957-958.
99. Megalla S, Shaqra H, Bhalodkar NC,. Non-ST-segment elevation myocardial infarction in the setting of sexual intercourse following the use of cocaine and sildenafil. Rev Cardiovasc Med. 2011; 12 (2): e113-e117.
100. Arora S, Goyal H, Aggarwal P, Kukar A,. ST-segment elevation myocardial infarction in a 37-year-old man with normal coronaries-it is not always cocaine! Am J Emerg Med. 2012; 30 (9): e3-e5.
101. Rufa A, Cerase A, Monti L, et al. Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction. J Neurol Sci. 2007; 260 (1-2): 293-295.
102. Pinto LM, Morekar S, Mahashur AA,. Central retinal vein occlusion in a patient after being commenced on sildenafil citrate for pulmonary arterial hypertension. Indian J Chest Dis Allied Sci. 2009; 51 (4): 249-251.
103. Lee J, Kwon JH, Lee CH, et al. A case of acute pulmonary thromboembolism after taking tadalafil. Tuberc Respir Dis (Seoul). 2012; 73 (4): 231-233.
104. Charles R, Holt S, Kirkham N,. Myocardial infarction and marijuana. Clin Toxicol. 1979; 14 (4): 433-438.
105. Tatli E, Yilmaztepe M, Altun G, Altun A,. Cannabis-induced coronary artery thrombosis and acute anterior myocardial infarction in a young man. Int J Cardiol. 2007; 120 (3): 420-422.
106. Dwivedi S, Kumar V, Aggarwal A,. Cannabis smoking and acute coronary syndrome: two illustrative cases. Int J Cardiol. 2008; 128 (2): e54-e57.
107. Bailly C, Merceron O, Hammoudi N, Dorent R, Michel PL,. Cannabis induced acute coronary syndrome in a young female. Int J Cardiol. 2010; 143 (1): e4-e6.
108. Hodcroft CJ, Rossiter MC, Buch AN,. Cannabis-associated myocardial infarction in a young man with normal coronary arteries. J Emerg Med. 2014; 47 (3): 277-281.
109. Cazalets C, Laurat E, Cador B, et al. Cannabis arteritis: four new cases [in French]. Rev Med Interne. 2003; 24 (2): 127-130.
110. Lee C, Moll S,. Migratory superficial thrombophlebitis in a cannabis smoker. Circulation. 2014; 130 (2): 214-215.
111. Zhu L, Lv YN, Wang LY,. Stent thrombosis with biodegradable polymer drug-eluting stents versus durable polymer sirolimus-eluting stents: an update meta-analysis. Cardiology. 2015; 130 (2): 96-105.